Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GADD45GIP1 Blocking Peptide (N-term)
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q8TAE8 |
|---|
| Gene ID | 90480 |
|---|---|
| Other Names | Growth arrest and DNA damage-inducible proteins-interacting protein 1, 39S ribosomal protein L59, mitochondrial, MRP-L59, CKII beta-associating protein, CR6-interacting factor 1, CRIF1, Papillomavirus L2-interacting nuclear protein 1, PLINP, PLINP-1, p53-responsive gene 6 protein, GADD45GIP1, MRPL59, PLINP1, PRG6 |
| Target/Specificity | The synthetic peptide sequence is selected from aa 33-45 of HUMAN GADD45GIP1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | GADD45GIP1 |
|---|---|
| Synonyms | MRPL59, PLINP1, PRG6 |
| Function | Acts as a negative regulator of G1 to S cell cycle phase progression by inhibiting cyclin-dependent kinases. Inhibitory effects are additive with GADD45 proteins but occurs also in the absence of GADD45 proteins. Acts as a repressor of the orphan nuclear receptor NR4A1 by inhibiting AB domain-mediated transcriptional activity. May be involved in the hormone-mediated regulation of NR4A1 transcriptional activity. May play a role in mitochondrial protein synthesis. |
| Cellular Location | Mitochondrion. Nucleus Note=Using N-terminally tagged constructs, has been found in the nucleus (PubMed:12482659). C-terminally tagged constructs are targeted exclusively to mitochondria (PubMed:22453275). This discrepancy may be explained by masking of a potential N-terminal mitochondrial targeting signal by the tag (PubMed:22453275). |
| Tissue Location | Widely expressed. Highly expressed in the thyroid gland, heart, lymph nodes, trachea and adrenal tissues. Expressed at lower level in liver skeletal muscle, kidney, pancreas, testis, ovary and stomach. Barely detectable in adrenal adenoma and papillary thyroid cancer. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Acts as a negative regulator of G1 to S cell cycle phase progression by inhibiting cyclin-dependent kinases. Inhibitory effects are additive with GADD45 proteins but occurs also in the absence of GADD45 proteins. Acts as a repressor of the orphan nuclear receptor NR4A1 by inhibiting AB domain-mediated transcriptional activity. May be involved in the hormone-mediated regulation of NR4A1 transcriptional activity. May play a role in mitochondrial protein synthesis.
References
Goernemann J.,et al.Virology 303:69-78(2002).
Chung H.K.,et al.J. Biol. Chem. 278:28079-28088(2003).
Frigimelica E.,et al.Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
Horikoshi N.,et al.Biochem. Biophys. Res. Commun. 261:864-869(1999).
Park K.C.,et al.Mol. Endocrinol. 19:12-24(2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
